Trevi Total Current Liabilities from 2010 to 2025
| TRVI Stock | USD 6.61 0.20 2.94% |
Total Current Liabilities | First Reported 2017-12-31 | Previous Quarter 9.1 M | Current Value 10.5 M | Quarterly Volatility 3.6 M |
Check Trevi Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trevi Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 3.8 M, Discontinued Operations of 0.0 or Selling General Administrative of 8.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0407 or PTB Ratio of 4.39. Trevi financial statements analysis is a perfect complement when working with Trevi Therapeutics Valuation or Volatility modules.
Trevi | Total Current Liabilities |
Latest Trevi Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Trevi Therapeutics over the last few years. Total Current Liabilities is an item on Trevi Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Trevi Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Trevi Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trevi Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Trevi Total Current Liabilities Regression Statistics
| Arithmetic Mean | 13,323,106 | |
| Geometric Mean | 11,213,145 | |
| Coefficient Of Variation | 52.27 | |
| Mean Deviation | 6,194,894 | |
| Median | 13,400,000 | |
| Standard Deviation | 6,963,470 | |
| Sample Variance | 48.5T | |
| Range | 17.7M | |
| R-Value | (0.73) | |
| Mean Square Error | 24.4T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | (1,065,027) | |
| Total Sum of Squares | 727.3T |
Trevi Total Current Liabilities History
About Trevi Therapeutics Financial Statements
Investors use fundamental indicators, such as Trevi Therapeutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Trevi Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 10.5 M | 7.4 M |
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out the analysis of Trevi Therapeutics Correlation against competitors. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.